Glutathione, oxidative stress and neurodegeneration

European Journal of Biochemistry

Volumn 267, Issue 16, 2000, Pages 4904-4911

  Schulz, J B ^a   Lindenau, J ^a   Seyfried, J ^a   Dichgans, J ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Glutathione; Neurodegeneration; Parkinson's disease

Indexed keywords

GLUTATHIONE PEROXIDASE; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN METABOLISM; DISEASE ASSOCIATION; GLUTATHIONE METABOLISM; HUMAN; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; FRIEDREICH ATAXIA; GLUTATHIONE; HUMANS; MITOCHONDRIA; MOTOR NEURON DISEASE; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0033899208     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01595.x     Document Type: Short Survey

References (76)

1. Glutathione metabolism in brain: Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species
2. Free radicals and antioxidants in the year 2000. A historical look to the future
3. Bcl-2 inhibition of neuronal death: Decreased generation of reactive oxygen species
4. Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis
5. Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis
6. A decrease in intracellular glutathione concentration precedes the onset of apoptosis in murine thymocytes
7. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody
8. Bcl-xL overexpression attenuates glutathione depletion in FL5.12 cells following interleukin-3 withdrawal
9. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion
10. Glutathione depletion and neuronal cell death: The role of reactive oxygen intermediates and mitochondrial function
11. Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells
12. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
13. Oxidative stress, caloric restriction, and aging
14. The pharmacokinetics and pharmaco-dynamics of procysteine in amyotrophic lateral sclerosis
15. Aging, energy and oxidative stress in neuro-degenerative diseases
16. Dopamine turnover and glutathione oxidation: Implications for Parkinson disease
17. Parkinson's disease: A disorder due to nigral glutathione deficiency?
18. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
19. Brain amino acids and glutathione in progressive supranuclear palsy
20. Reduced and oxidized glutathione in human and monkey brain
21. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
22. Glutathione-related enzymes in brain in Parkinson's disease
23. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
24. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
25. Glutathione deficiency leads to mitochondrial damage in brain
26. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
27. Cellular and regional distribution of reduced glutathione in the nervous system of the rat: Histochemical localization by mercury orange and o-phthaldialdehyde-induced histofluorescence
28. Antisera to glutathione: Characterization and immunocytochemical application to the rat cerebellum
29. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures
30. Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures
31. The MPTP model: Versatile contributions to the treatment
32. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
33. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration
34. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum
35. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain
36. +-toxicity in nigral dopaminergic neurons
37. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-l,2,5,6-tetrahydropyridine
38. Enhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegeneration
39. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species
40. Effects of L-cysteine on the oxidation chemistry of dopamine: New reaction pathways of potential relevance to idiopathic Parkinson's disease
41. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease
42. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease
43. Parkinson's disease, pesticides, and glutathione transferase polymorphisms
44. Mitochondrial dysfunction in movement disorders
45. Effect of 1-methyl-4-phenyl-pyridinium on glutathione in rat pheochromocytoma PC12 cells
46. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration
47. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
48. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease
49. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease
50. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease
51. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease
52. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease
53. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis
54. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice
55. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis
56. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant
57. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis
58. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients
59. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis
60. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death
61. 35S] glutathione binding sites in spinal cords from patients with sporadic amyotrophic lateral sclerosis
62. Plasma superoxide dismutase and glutathione peroxidase activity in sporadic amyotrophic lateral sclerosis
63. Glutathione peroxidase in amyotrophic lateral sclerosis: The effects of selenium supplementation
64. Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis
65. Studies on cellular free radical protection mechanisms in the anterior horn from patients with amyotrophic lateral sclerosis
66. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis
67. Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis
68. Schizophrenia: Glutathione deficit in cerebro spinal fluid and prefrontal cortex in vivo
69. Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats
70. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine
71. L-2-oxothiazolidine-4-carboxylate. A cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet
72. N-Acetylcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain
73. L-cysteine, a bicarbonate-sensitive endogenous excitotoxin
74. Increase in rat brain glutathione following intracerebroventricular administration of gamma-glutamylcysteine
75. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione
76. Oxidative damage in neurodegenerative disease